



November 2022

Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
USA

Dear Patient:

This letter is to inform you about an important change to the Tecentriq® (atezolizumab) label for the treatment of locally advanced or metastatic urothelial cancer (mUC).

Genentech, a member of the Roche Group, announced the voluntary withdrawal of the U.S. indication for Tecentriq for the treatment of adult patients with certain types of bladder and urinary tract cancer (urothelial carcinoma that has spread or cannot be removed by surgery in patients who are not able to take cisplatin chemotherapy and have cancer that tests positive for “PD-L1”, or in patients who are not able to take chemotherapy that contains any platinum regardless of “PD-L1” status). This decision is due to new results from a large clinical trial that was designed to confirm the effectiveness of Tecentriq for treating bladder cancer. It is not due to safety concerns, and does not affect other approved indications for Tecentriq.

If you are currently receiving Tecentriq for bladder or urinary tract cancer, you should talk to your doctor about what the withdrawal means for you and your current treatment. You should discuss with your doctor the risks and the benefits of treatment with Tecentriq.

The withdrawal of the indication could mean that some insurers may no longer pay for Tecentriq in locally advanced or metastatic bladder cancer. If you are concerned about insurance coverage, please contact your insurance company’s patient support line or Genentech for assistance. Genentech is committed to supporting patients who are currently benefiting from Tecentriq therapy and may be facing obstacles to receiving treatment. If your insurance has changed or you can’t pay for your Genentech medicine, we are here to help.

Please call the Genentech Patient Resource Center at 1-877-436-3683 and you will be connected to one of our patient support specialists who can help answer your questions.

We understand this may be a difficult time for you and your loved ones. Genentech’s scientists, doctors and employees remain committed to advancing the scientific understanding of cancer and discovering new medicines.

This letter is not intended as a complete description of the benefits and risks related to the use of Tecentriq. Please refer to the Medication Guide (https://www.gene.com/download/pdf/tecentriq_medguide.pdf) for more information. The revised Medication Guide is not yet available when this letter is released, and will be posted at the above link as soon as possible.

Sincerely,

Jamie Freedman MD, PhD
Head of U.S. Medical Affairs